Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 299

1.

Ragweed allergy immunotherapy tablet MK-3641 (Ragwitek®) for the treatment of allergic rhinitis.

Nelson HS.

Expert Rev Clin Immunol. 2018 Dec;14(12):1003-1011. doi: 10.1080/1744666X.2018.1538788. Epub 2018 Nov 8. Review.

PMID:
30345820
2.

Recent advances in allergic rhinitis.

Hoyte FCL, Nelson HS.

F1000Res. 2018 Aug 23;7. pii: F1000 Faculty Rev-1333. doi: 10.12688/f1000research.15367.1. eCollection 2018. Review.

3.

Immunotherapy for house-dust mite allergy.

Nelson HS.

Allergy Asthma Proc. 2018 Jul 1;39(4):264-272. doi: 10.2500/aap.2018.39.4145.

PMID:
30095391
4.

SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.

Bernstein DI, Kleine-Tebbe J, Nelson HS, Bardelas JA Jr, Sussman GL, Lu S, Rehm D, Svanholm Fogh B, Nolte H.

Ann Allergy Asthma Immunol. 2018 Jul;121(1):105-110. doi: 10.1016/j.anai.2018.04.007. Epub 2018 Apr 12.

5.

Treatment with the SQ house dust mite sublingual immunotherapy tablet may be initiated year-round.

Nolte H, Bernstein DI, Kleine-Tebbe J, Fejerskov PA, Li Q, Lu S, Nelson HS.

J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1758-1760.e1. doi: 10.1016/j.jaip.2017.12.035. Epub 2018 Mar 1. No abstract available.

6.

International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, Azar A, Baroody FM, Bachert C, Canonica GW, Chacko T, Cingi C, Ciprandi G, Corey J, Cox LS, Creticos PS, Custovic A, Damask C, DeConde A, DelGaudio JM, Ebert CS, Eloy JA, Flanagan CE, Fokkens WJ, Franzese C, Gosepath J, Halderman A, Hamilton RG, Hoffman HJ, Hohlfeld JM, Houser SM, Hwang PH, Incorvaia C, Jarvis D, Khalid AN, Kilpeläinen M, Kingdom TT, Krouse H, Larenas-Linnemann D, Laury AM, Lee SE, Levy JM, Luong AU, Marple BF, McCoul ED, McMains KC, Melén E, Mims JW, Moscato G, Mullol J, Nelson HS, Patadia M, Pawankar R, Pfaar O, Platt MP, Reisacher W, Rondón C, Rudmik L, Ryan M, Sastre J, Schlosser RJ, Settipane RA, Sharma HP, Sheikh A, Smith TL, Tantilipikorn P, Tversky JR, Veling MC, Wang Y, Westman M, Wickman M, Zacharek M.

Int Forum Allergy Rhinol. 2018 Feb;8(2):108-352. doi: 10.1002/alr.22073.

7.

Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet.

Nolte H, Bernstein DI, Sussman GL, Svanholm Fogh B, Lu S, Husøy B, Nelson HS.

J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):2081-2086.e1. doi: 10.1016/j.jaip.2018.01.037. Epub 2018 Feb 10.

8.

Current and future challenges of subcutaneous and sublingual allergy immunotherapy for allergists in the United States.

Nelson HS.

Ann Allergy Asthma Immunol. 2018 Sep;121(3):278-280. doi: 10.1016/j.anai.2017.12.013. Epub 2018 Jun 12. No abstract available.

PMID:
29409924
9.

Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents.

Matsuoka T, Bernstein DI, Masuyama K, Nolte H, Okamiya K, Seitzberg D, Nelson HS.

Pediatr Allergy Immunol. 2017 Nov;28(7):661-667. doi: 10.1111/pai.12747. Epub 2017 Aug 31.

PMID:
28660739
10.

Immunotherapy coming of age: notable advances during the first hundred years.

Nelson HS.

Expert Rev Clin Immunol. 2017 May;13(5):389-392. doi: 10.1080/1744666X.2017.1292136. Epub 2017 Feb 15. No abstract available.

PMID:
28443797
11.

Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma.

Brunton S, Nelson HS, Bernstein DI, Lawton S, Lu S, Nolte H.

Postgrad Med. 2017 Aug;129(6):581-589. doi: 10.1080/00325481.2017.1308208. Epub 2017 Mar 27. Review.

PMID:
28326908
12.

Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles.

Nelson HS, Calderon MA, Bernstein DI, Casale TB, Durham SR, Andersen JS, Esch R, Cox LS, Nolte H.

Curr Allergy Asthma Rep. 2017 Mar;17(3):18. doi: 10.1007/s11882-017-0687-0. Review.

PMID:
28293909
13.

Allergen Immunotherapy for a Teenager with Seasonal Allergic Rhinitis Due to Grass Pollen: Subcutaneous or Sublingual Route?

Nelson HS, Durham SR.

J Allergy Clin Immunol Pract. 2017 Jan - Feb;5(1):52-57. doi: 10.1016/j.jaip.2016.10.012. Review. No abstract available.

PMID:
28065341
14.

Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial.

Zieglmayer P, Nolte H, Nelson HS, Bernstein DI, Kaur A, Jacobi H, Lemell P, Schmutz R, Zieglmayer R, Horak F.

Ann Allergy Asthma Immunol. 2016 Dec;117(6):690-696.e1. doi: 10.1016/j.anai.2016.10.015.

PMID:
27979028
15.

Inhalation devices, delivery systems, and patient technique.

Nelson HS.

Ann Allergy Asthma Immunol. 2016 Dec;117(6):606-612. doi: 10.1016/j.anai.2016.05.006. Review.

PMID:
27979017
16.

Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets.

Nolte H, Casale TB, Lockey RF, Fogh BS, Kaur A, Lu S, Nelson HS.

J Allergy Clin Immunol Pract. 2017 Jan - Feb;5(1):84-89.e3. doi: 10.1016/j.jaip.2016.08.017. Epub 2016 Nov 9.

PMID:
27838323
17.

Allergen immunotherapy (AIT) for the multiple-pollen sensitive patient.

Nelson HS.

Expert Rev Clin Pharmacol. 2016 Nov;9(11):1443-1451. doi: 10.1080/17512433.2016.1237874. Epub 2016 Oct 6. Review.

PMID:
27687128
18.

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses.

Durham SR, Creticos PS, Nelson HS, Li Z, Kaur A, Meltzer EO, Nolte H.

J Allergy Clin Immunol. 2016 Oct;138(4):1081-1088.e4. doi: 10.1016/j.jaci.2016.04.061. Epub 2016 Jul 15.

19.

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.

Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, Rehm D, Kaur A, Li Z, Lu S.

J Allergy Clin Immunol. 2016 Dec;138(6):1631-1638. doi: 10.1016/j.jaci.2016.06.044. Epub 2016 Aug 10.

PMID:
27521719
20.

Allergen immunotherapy now and in the future.

Nelson HS.

Allergy Asthma Proc. 2016 Jul;37(4):268-72. doi: 10.2500/aap.2016.37.3966. Review.

PMID:
27401313

Supplemental Content

Loading ...
Support Center